 | • レポートコード：MRC2203A603 • 出版社/出版日：Mordor Intelligence / 2022年1月 • レポート形態：英文、PDF、111ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Site Licence | ￥962,000 (USD6,500) | ▷ お問い合わせ |
| Corporate License | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社は、世界の急性興奮・攻撃的症状治療市場規模が予測期間中に年平均4.9％成長すると予測しています。本調査資料では、急性興奮・攻撃的症状治療の世界市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、投与経路別（経口、筋肉内、その他）分析、薬剤分類別（抗精神病薬、ベンゾジアゼピン、その他）分析、エンドユーザー別（病院・外来手術センター、精神科医療施設、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米）分析、競争状況、市場機会・将来の傾向などの項目を掲載しています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の急性興奮・攻撃的症状治療市場規模：投与経路別（経口、筋肉内、その他） ・世界の急性興奮・攻撃的症状治療市場規模：薬剤分類別（抗精神病薬、ベンゾジアゼピン、その他） ・世界の急性興奮・攻撃的症状治療市場規模：エンドユーザー別（病院・外来手術センター、精神科医療施設、その他） ・世界の急性興奮・攻撃的症状治療市場規模：地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米） ・競争状況（Eli Lilly and Company、Pfizer, Inc.、Otsuka Holdings、GlaxoSmithKline、H. Lundbeck A/S、Johnson & Johnson、Bristol-Myers Squibb） ・市場機会・将来の傾向 |
Global Acute Agitation and Aggression Treatment market is expected to witness a CAGR of 4.9% during the forecast period. Certain factors that are driving the market growth include rise in burden of mental illness and increase in agitation in patients, increase in focus on creating awareness about agitation and aggression, and ongoing research on the development of novel treatment for agitation.
According to the statistics provided by the Mental Health Foundation in 2018, mental health problems are one of the primary causes of rising medical concerns. In addition, according to the United States Census Bureau’s Statistics, as of 2017, the total number of people aged 65 and older exceeds 50 million, and between 2020-2030, the number of elderly population is projected to increase by almost 18 million. Although much smaller in the total size, the number of people aged between 85 years and older is expected to be more than tripled, from an estimated 6 million in 2017, to nearly 20 million by 2060. Furthermore, mental and behavioral health problems are considered to be the primary cause of disability in the elderly population.
Key Market Trends
Anti-psychotics is Expected to Hold Significant Market Share in the Drug Class Segment
The typical antipsychotics cause sedation, given a high enough dose. Haloperidol, a high potency butyrophenone, has been frequently used as an intramuscular as-needed medication for agitation and aggressive behavior in an emergency department setting for a wide variety of patients. Droperidol, another antipsychotic in the butyrophenone class, is not approved by the US Food and Drug Administration for psychiatric conditions but has been used for sedating agitated patients in an emergency room setting.
Moreover, robust development pipeline coupled with the activity of the manufacturers in launch and collaborations projected to boost the segment growth. For Instance, in May 2017, Otsuka and Lundbeck announce results of brexpiprazole on symptoms of agitation related to Alzheimer’s-type dementia. Furthermore, the growing burden of risk factors fr agitation and aggression such as neurological disorders projected to bolster the market growth over the forecast period.
North America Dominates the Market and Expected to do Same in the Forecast Period
As per the Mental Health America, more than 44 million American adults have a mental health condition (2017). The most commonly reported agents are benzodiazepines, followed by butyrophenone antipsychotics (e.g., haloperidol, droperidol) as reported by directors of emergency medicine residencies and pediatric emergency medicine fellowships in the United States. Moreover, within the United States, approximately 5.7 million people are living with dementia (Alzheimer’s Association, 2018). All these factors are expected to drive the market growth in the region.
Competitive Landscape
The global acute agitation and aggression treatment market is moderately competitive and consists of a few major players. Companies like Eli Lilly and Company, Pfizer, Inc., Otsuka Holdings, GlaxoSmithKline, H. Lundbeck A/S, Johnson & Johnson, Bristol-Myers Squibb, among others, hold the substantial market share in the Acute Agitation and Aggression Treatment market.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rise in Geriatric Population and Increase in Agitation in Patients
4.2.2 Increase in Focus on Creating Awareness About Agitation and Aggression
4.2.3 Ongoing Research on the Development of Novel Treatment for Agitation
4.3 Market Restraints
4.3.1 Preference for Non-Pharmacological Interventions
4.3.2 Social Stigma Associated With Mental Illness
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Route of Administration
5.1.1 Oral
5.1.2 Intramuscular
5.1.3 Others
5.2 By Drug Class
5.2.1 Anti-psychotics
5.2.2 Benzodiazepines
5.2.3 Others
5.3 By End Users
5.3.1 Hospitals & Ambulatory Surgical Centers
5.3.2 Psychiatric Care Facilities
5.3.3 Others
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle-East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle-East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Eli Lilly and Company
6.1.2 Pfizer, Inc.
6.1.3 Otsuka Holdings
6.1.4 GlaxoSmithKline
6.1.5 H. Lundbeck A/S
6.1.6 Johnson & Johnson
6.1.7 Bristol-Myers Squibb
7 MARKET OPPORTUNITIES AND FUTURE TRENDS